2018-10-29 16:00Financial Performance - Net profit attributable to shareholders was RMB 3,439,293 thousand, representing a 131.50% increase year-on-year[9]. - Operating revenue for the first nine months was RMB 29,875,825 thousand, up 87.11% from the same period last year[9]. - Basic earnings per share rose to RMB 2.115, reflecting a 131.50% increase year-on-year[9]. - The net profit after deducting non-recurring gains and losses was RMB 2,181,834 thousand, a 50.99% increase year-on-year[9]. - The net profit for the first three quarters of 2018 reached RMB 3,509,315,000, a year-on-year increase of 129.50%[20]. - The net profit for Q3 2018 was CNY 849,951,690.33, a significant increase from CNY 338,153,351.37 in Q3 2017, representing a growth of 151.5%[33]. - The net profit attributable to shareholders for the first nine months of 2018 was RMB 3.98 billion, a 121.18% increase from RMB 1.80 billion in 2017[18]. - The total profit for the first nine months of 2018 was RMB 3.98 billion, driven by the acquisition of pharmaceutical companies and increased profits from subsidiaries[18]. Revenue and Costs - The company's operating revenue for the first nine months of 2018 reached RMB 29.88 billion, an increase of 87.11% compared to RMB 15.97 billion in the same period of 2017[17]. - The operating costs for the same period increased by 121.04%, amounting to RMB 22.23 billion, up from RMB 10.06 billion in 2017[17]. - Total operating revenue for the third quarter reached CNY 15,035,810,958.15, a significant increase from CNY 4,851,593,362.61 in the same period last year[32]. - Total operating costs amounted to CNY 14,365,102,561.08, compared to CNY 4,516,888,584.18 in the previous year[32]. Assets and Liabilities - Total assets reached RMB 49,593,828 thousand, an increase of 75.18% compared to the previous year[9]. - The total liabilities increased to RMB 24,680,208,243.92 from RMB 8,268,854,244.55 at the beginning of the year[25]. - The total assets as of September 30, 2018, amounted to RMB 49,593,828,052.35, compared to RMB 28,310,300,555.29 at the beginning of the year[24]. - The company reported a significant increase in accounts receivable, totaling RMB 14,147,501,540.05, compared to RMB 2,816,424,481.59 at the beginning of the year[24]. Cash Flow - The net cash flow from operating activities was RMB 3,355,716 thousand, an increase of 85.25% compared to the previous year[9]. - The net cash flow from investment activities increased to RMB 1,095,595 thousand, a significant improvement from a negative RMB 1,537,016 thousand in the previous year[20]. - The total cash inflow from operating activities for the first nine months was ¥30,133,337,704.48, compared to ¥12,652,125,758.50 in the previous year, marking an increase of 137.6%[41]. - The net cash flow from operating activities for the third quarter was ¥1,034,314,259.43, an increase from ¥620,865,776.10 in the previous year, representing a growth of approximately 66.5%[46]. Shareholder Information - The number of shareholders as of September 30, 2018, was 61,498, with 61,473 holding A shares and 25 holding H shares[11]. - Guangzhou Pharmaceutical Group Co., Ltd. held 45.04% of the shares, totaling 732,305,103 shares[12]. - The total number of shareholders with unrestricted shares was reported, with Guangzhou Pharmaceutical Group holding 583,966,636 shares[14]. Research and Development - Research and development expenses rose by 60.61% to RMB 392.27 million, compared to RMB 244.24 million in the previous year[17]. - Research and development expenses for Q3 2018 amounted to CNY 149,980,168.46, up from CNY 110,482,002.37 in Q3 2017, reflecting a growth of 35.7%[33]. - Research and development expenses increased to ¥185,736,736.99 for the first nine months, compared to ¥82,305,010.23 in the previous year, indicating a rise of 125.5%[38]. Government Subsidies and Other Income - The company received government subsidies amounting to RMB 174,731 thousand during the reporting period[11]. - The company’s other income surged by 206.32% to RMB 136.12 million, primarily due to increased government subsidies[18]. - The company recognized other income of CNY 19,266,632.10 in Q3 2018, compared to CNY 14,940,509.46 in Q3 2017, which is an increase of 28.5%[33]. Acquisitions and Investments - The company acquired a 96.093% stake in Wanglaoji Pharmaceutical, which was included in the consolidated financial statements during the reporting period[21]. - The company established a new subsidiary, Guangzhou Baiyunshan Runkang Maternity Club Co., Ltd., with a registered capital of RMB 10 million[22]. - The company reported an investment income of RMB 1.19 billion, a significant increase of 528.81% from RMB 189.25 million in 2017[18]. - The investment income for the first nine months was ¥690,632,136.01, significantly higher than ¥165,162,887.10 in the previous year, representing an increase of 318.5%[39].